Analysts Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Target Price at $89.17

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been given a consensus recommendation of “Moderate Buy” by the twenty-three analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, fourteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $89.1739.

Several equities research analysts have weighed in on the company. Wall Street Zen raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. BMO Capital Markets started coverage on BioMarin Pharmaceutical in a report on Wednesday, August 19th. They issued an “outperform” rating and a $98.00 price objective on the stock. Weiss Ratings raised shares of BioMarin Pharmaceutical from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, September 3rd. UBS Group set a $88.00 price target on BioMarin Pharmaceutical in a research report on Wednesday, August 26th. Finally, Citigroup upped their price objective on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th.

BioMarin Pharmaceutical Price Performance

Shares of BMRN opened at $65.68 on Friday. The company has a market cap of $12.71 billion, a price-to-earnings ratio of 177.51, a price-to-earnings-growth ratio of 0.47 and a beta of 0.24. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The company has a 50 day moving average of $63.30 and a two-hundred day moving average of $58.50.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. During the same period in the previous year, the company earned $1.44 earnings per share. The business’s revenue for the quarter was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, analysts predict that BioMarin Pharmaceutical will post 4.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC increased its holdings in BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares during the last quarter. Northwestern Mutual Investment Management Company LLC lifted its holdings in BioMarin Pharmaceutical by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock worth $2,554,000 after acquiring an additional 183 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of BioMarin Pharmaceutical by 70.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 187 shares during the last quarter. Caerus Investment Advisors LLC increased its position in BioMarin Pharmaceutical by 2.8% in the fourth quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock worth $608,000 after buying an additional 278 shares during the period. Finally, Chicago Partners Investment Group LLC increased its position in BioMarin Pharmaceutical by 2.4% in the first quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock worth $660,000 after buying an additional 290 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare and serious diseases. Founded in 1997 and headquartered in San Rafael, California, the company specializes in treatments for conditions that often have limited or no available therapeutic options, including inherited metabolic disorders, skeletal diseases, and certain bleeding disorders.

BioMarin’s marketed products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for late-infantile neuronal ceroid lipofuscinosis type 2, Palynziq and Kuvan for phenylketonuria, and Voxzogo for achondroplasia in children with open growth plates.